

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

COMP/M.5949 - DEUTSCHE BANK / ACTAVIS

SECTION 1.2

Description of the concentration

On 18 August 2010, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (the "Regulation"), according to which Deutsche Bank AG, London Branch will acquire negative sole control, within the meaning of Article 3(1)(b) of the Regulation, over Actavis Group hF ("Actavis"). Actavis is active in the development, manufacture and sale of generic pharmaceuticals.

